Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Relmada Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DR. KATES' EXPERIENCE AS CHAIR OF THE LANDMARK PHASE 3 BRIDGE BLADDER CANCER TRIAL AND DEDICATION TO PATIENT CARE WILL BE INVALUABLE TO THE NDV-01 PHASE 3 PROGRAM

RELMADA THERAPEUTICS APPOINTS DISTINGUISHED UROLOGIC ONCOLOGIST, MAX KATES, MD, TO THE CLINICAL ADVISORY BOARD TO SUPPORT DEVELOPMENT OF NDV-01

CORAL GABLES, FLA., SEPT. 16, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY-RELATED AND CENTRAL NERVOUS SYSTEM INDICATIONS, TODAY ANNOUNCED THAT ON SEPTEMBER 15, 2025 IT RECEIVED WRITTEN NOTICE FROM THE NASDAQ STOCK MARKET LLC (NASDAQ) CONFIRMING THAT THE COMPANY HAS REGAINED COMPLIANCE WITH NASDAQ'S $1.00 MINIMUM BID PRICE REQUIREMENT UNDER NASDAQ LISTING RULE 5550 (A)(2) (THE LISTING RULE).

RELMADA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

CORAL GABLES, FLA., SEPT. 10, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY-RELATED AND CENTRAL NERVOUS SYSTEM INDICATIONS, TODAY ISSUED A LETTER TO SHAREHOLDERS FROM SERGIO TRAVERSA, CHIEF EXECUTIVE OFFICER.

RELMADA ISSUES MID-YEAR CEO LETTER TO SHAREHOLDERS

CORAL GABLES, FLA., JULY 31, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY AND CENTRAL NERVOUS SYSTEM INDICATIONS, TODAY ANNOUNCED PLANS TO HOST A CONFERENCE CALL AND WEBCAST ON THURSDAY, AUGUST 7, 2025 AT 4:30 PM ET TO DISCUSS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025 AND RECENT BUSINESS PROGRESS.

RELMADA THERAPEUTICS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON THURSDAY, AUGUST 7, 2025

DR. LOTAN'S DISTINGUISHED EXPERTISE IN BLADDER CANCER CARE AND CLINICAL DEVELOPMENT BRINGS FURTHER SCIENTIFIC ACUMEN TO RELMADA'S NDV-01 PROGRAM PHASE 3 TRIAL FOR NDV-01 EXPECTED TO BEGIN IN H1 2026 CORAL GABLES, FLA., JULY 15, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY AND CENTRAL NERVOUS SYSTEM INDICATIONS, TODAY ANNOUNCED THE APPOINTMENT OF YAIR LOTAN, MD, A DISTINGUISHED UROLOGIC ONCOLOGIST, AS CHAIR OF RELMADA'S CLINICAL ADVISORY BOARD (CAB).

RELMADA THERAPEUTICS APPOINTS RENOWNED UROLOGIC ONCOLOGIST, YAIR LOTAN, MD, TO CHAIR THE CLINICAL ADVISORY BOARD AND SUPPORT DEVELOPMENT OF NDV-01

APPOINTMENT HIGHLIGHTS DIMERX'S NEXT PHASE OF GROWTH AS IT ADVANCES NON-ADDICTIVE PAIN THERAPEUTICS WITH SUPPORT FROM THE NIH HEAL INITIATIVE APPOINTMENT HIGHLIGHTS DIMERX'S NEXT PHASE OF GROWTH AS IT ADVANCES NON-ADDICTIVE PAIN THERAPEUTICS WITH SUPPORT FROM THE NIH HEAL INITIATIVE

DIMERX APPOINTS BIOTECH LEADER SERGIO TRAVERSA, PHARMD, TO BOARD OF DIRECTORS

DR. PRUTHI BRINGS VAST CLINICAL DEVELOPMENT EXPERIENCE ADVANCING NOVEL THERAPIES FOR NMIBC TO RELMADA AND THE NDV-01 PROGRAM PHASE 3 TRIAL FOR NDV-01 EXPECTED TO BEGIN IN H1 2026 CORAL GABLES, FLA., JUNE 17, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY AND CENTRAL NERVOUS SYSTEM INDICATIONS, TODAY ANNOUNCED THE APPOINTMENT OF RAJ S.

RELMADA THERAPEUTICS APPOINTS UROLOGY EXPERT RAJ S. PRUTHI, MD AS CMO-UROLOGY

POSITIVE INITIAL PHASE 2 PROOF-OF-CONCEPT DATA FOR NDV-01 AT AUA 2025 SHOWING A 90% OVERALL RESPONSE RATE AT ANY TIME IN NON-MUSCLE INVASIVE BLADDER CANCER (US PREVALENCE 600K PATIENTS)

RELMADA THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

CORAL GABLES, FLA., MAY 08, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA, OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO ADVANCING INNOVATIVE BREAKTHROUGH THERAPIES, TODAY ANNOUNCED PLANS TO HOST A CONFERENCE CALL AND WEBCAST ON MONDAY, MAY 12, 2025 AT 4:30 PM ET TO DISCUSS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025 AND RECENT BUSINESS PROGRESS.

RELMADA THERAPEUTICS TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS ON MONDAY, MAY 12, 2025

90% OF PATIENTS ACHIEVED HIGH GRADE DISEASE-FREE STATUS AT ANY TIME POINT WITH NDV-01, DEMONSTRATING STRONG PROOF-OF-CONCEPT FOR SUSTAINED-RELEASE GEM/DOCE FORMULATION*

Relmada Therapeutics, Inc.

RLMD

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Relmada Therapeutics, Inc.

RLMD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

RLMD